GO:0061755 positive regulation of circulating fibrinogen levels: Coagulation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0061755 describes any biological process that increases the amount of fibrinogen circulating in the bloodstream, a central event in hemostasis and inflammation.
• Circulating fibrinogen is a liver-derived acute-phase protein whose plasma levels rise during infection, trauma, and malignancy, and it serves as a key coagulation biomarker.
• Elevated fibrinogen levels are associated with inflammatory and coagulation disorders, including acute aortic dissection and certain malignancies [2,4,5,8].
• Proteolytic processing of the fibrinogen alpha chain generates fragments that can influence fibrosis progression in liver disease.
• Experimental models for studying fibrinogen regulation include hepatocyte-specific knockout, point-mutation knock-in, and overexpression systems, combined with CRISPR screening and bioinformatics [1,6].
• Understanding positive regulation of circulating fibrinogen levels is essential for developing diagnostics and therapeutics targeting thrombotic and inflammatory diseases [2,5,8].
Description
Fibrinogen is a soluble plasma glycoprotein that serves as the precursor to fibrin, the structural backbone of blood clots. The Gene Ontology term GO:0061755, positive regulation of circulating fibrinogen levels, refers to any process that increases the quantity of fibrinogen circulating in the bloodstream. This process is critical for maintaining hemostasis but also contributes to pathological thrombosis and inflammation when dysregulated. Circulating fibrinogen levels are routinely measured in clinical settings as an indicator of inflammatory and procoagulant states, and they have prognostic value in conditions such as acute aortic dissection and malignancies [2,4,5]. Research into the molecular mechanisms that upregulate fibrinogen production and secretion is therefore of broad biomedical importance. The liver is the primary site of fibrinogen synthesis, and its production is influenced by cytokines, hormones, and extracellular matrix interactions [1,7]. In addition, proteolytic processing of fibrinogen can generate bioactive fragments that modulate fibrosis and inflammation, further highlighting the need to understand how circulating levels are positively regulated. This article synthesizes current knowledge on GO:0061755, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and experimental approaches for investigation.
positive regulation of circulating fibrinogen levels At A Glance
| GO ID | GO:0061755 |
|---|---|
| GO term | positive regulation of circulating fibrinogen levels |
| Ontology | biological_process |
| Synonym | none |
| Major function | Upregulation of fibrinogen concentration in blood plasma |
| Related process | Coagulation, acute-phase response, inflammation |
| Primary tissue | Liver (hepatocytes) |
| Key regulators | IL-6, STAT3, C/EBPbeta, extracellular matrix components |
| Clinical relevance | Thrombosis, acute aortic dissection, malignancy, liver fibrosis |
What Is GO:0061755?
GO:0061755 is a biological process term defined as any process that increases the quantity of fibrinogen circulating in the bloodstream. It encompasses the transcriptional, post-transcriptional, and secretory mechanisms that elevate plasma fibrinogen concentrations, as well as processes that reduce its clearance or degradation.
Why Is positive regulation of circulating fibrinogen levels Important in Cell Biology?
Positive regulation of circulating fibrinogen levels is a central node linking inflammation, coagulation, and tissue repair. Elevated fibrinogen is an independent risk factor for cardiovascular events and is associated with poor prognosis in several diseases, including acute aortic dissection and cancer [2,4,5,8]. Understanding the mechanisms that drive fibrinogen production can reveal therapeutic targets for thrombotic disorders and inflammatory conditions. Moreover, fibrinogen fragments can serve as biomarkers for disease progression, as shown in liver fibrosis where a specific fibrinogen alpha chain fragment precedes fibrosis advancement. Therefore, research on GO:0061755 has direct translational potential.
• Fibrinogen is a major determinant of blood viscosity and clot formation, and its upregulation increases thrombotic risk.
• Circulating fibrinogen levels are elevated in acute-phase responses to infection, trauma, and malignancy.
• High fibrinogen levels are associated with acute aortic dissection and can serve as a diagnostic biomarker [2,5].
• Fibrinogen alpha chain fragments are implicated in the progression of liver fibrosis.
• Fibrinogen interacts with extracellular matrix components to influence endothelial survival and perfusion.
• Angiopoietin-like protein 8, a metabolic regulator, is linked to inflammatory conditions and thoracic aortic dissection, which often involve fibrinogen dysregulation.
• Interleukin-33 and soluble ST2 axis modulate adipose tissue inflammation, which can impact fibrinogen levels.
• Phospholipase A2-IIA levels correlate with coagulation biomarkers in malignancies, suggesting crosstalk with fibrinogen regulation.
• Targeting fibrinogen production pathways may reduce cardiovascular events in high-risk patients.
• CRISPR-based models enable precise dissection of genes that positively regulate fibrinogen levels [1,6].
What Happens During positive regulation of circulating fibrinogen levels?
Transcriptional activation of fibrinogen genes
In simple terms: The liver cells receive signals to make more fibrinogen by turning on the genes that code for it.
In hepatocytes, inflammatory cytokines such as interleukin-6 (IL-6) activate signaling cascades that lead to the transcription of the fibrinogen alpha, beta, and gamma chain genes (FGA, FGB, FGG). This transcriptional upregulation is a primary mechanism for increasing circulating fibrinogen levels. The process is part of the acute-phase response and can be triggered by infection, trauma, or malignancy.
Post-transcriptional and secretory regulation
In simple terms: After the genes are turned on, the cell fine-tunes how much protein is made and released into the blood.
Following transcription, fibrinogen mRNA stability and translation efficiency can be modulated, and the assembled hexameric fibrinogen protein is secreted into the bloodstream. Positive regulation of circulating levels may involve enhanced secretion or reduced clearance. Extracellular matrix components can influence endothelial and hepatocyte behavior, indirectly affecting fibrinogen secretion.
Proteolytic processing and fragment generation
In simple terms: Enzymes can cut fibrinogen into smaller pieces that have their own biological activities.
Proteolytic cleavage of the fibrinogen alpha chain generates fragments, such as a 5.9 kDa C-terminal peptide, which can serve as biomarkers and may modulate fibrosis progression. This processing can affect the net circulating levels of intact fibrinogen and its derivatives.
Integration with inflammatory and metabolic signals
In simple terms: The body integrates signals from inflammation and metabolism to adjust fibrinogen levels.
Inflammatory mediators like IL-33 and soluble ST2, as well as metabolic regulators such as angiopoietin-like protein 8, can influence systemic inflammation and coagulation, thereby impacting fibrinogen levels [3,8]. Phospholipase A2-IIA, an inflammatory enzyme, correlates with coagulation biomarkers in malignancies, suggesting crosstalk.
Key Genes Involved in GO:0061755 positive regulation of circulating fibrinogen levels
The following genes and proteins are involved in the positive regulation of circulating fibrinogen levels, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FGA | Fibrinogen alpha chain; substrate for fibrin formation | Mutations cause dysfibrinogenemia; fragment biomarkers in liver fibrosis |
| FGB | Fibrinogen beta chain; structural component | Transcriptional regulation by IL-6; target for knockout studies |
| FGG | Fibrinogen gamma chain; structural component | Alternative splicing; involved in clot stability |
| IL6 | Pro-inflammatory cytokine; induces fibrinogen transcription | Key upstream regulator; knockout reduces fibrinogen levels |
| STAT3 | Transcription factor downstream of IL-6 | Mediates acute-phase response; point mutations affect DNA binding |
| CEBPB | Transcription factor; regulates acute-phase genes | Knockout models show reduced fibrinogen expression |
| IL33 | Alarmin cytokine; modulates inflammation | Linked to adipose tissue inflammation and coagulation |
| IL1RL1 | Encodes soluble ST2; decoy receptor for IL-33 | Biomarker for acute aortic dissection; affects inflammation [2,3] |
| PLA2G2A | Phospholipase A2 group IIA; inflammatory enzyme | Correlates with coagulation biomarkers in malignancies |
| MMP9 | Matrix metalloproteinase 9; extracellular matrix remodeling | Elevated in acute aortic dissection; may influence fibrinogen |
| TLR4 | Toll-like receptor 4; innate immune sensor | Serum levels associated with acute aortic dissection |
| ANGPTL8 | Angiopoietin-like protein 8; metabolic regulator | Increased in thoracic aortic dissection and inflammation |
| FBN1 | Fibrillin-1; extracellular matrix protein | Mutations cause Marfan syndrome; affects aortic wall and coagulation |
| ITGB1 | Integrin beta 1; cell-matrix adhesion | Modulates endothelial survival and perfusion |
| VEGFA | Vascular endothelial growth factor A | Influences endothelial function and perfusion |
| HGF | Hepatocyte growth factor | Promotes hepatocyte survival; may affect fibrinogen synthesis |
| ALB | Albumin; major plasma protein | Negative acute-phase reactant; inverse relationship with fibrinogen |
| CRP | C-reactive protein; acute-phase protein | Co-regulated with fibrinogen in inflammation |
How Is positive regulation of circulating fibrinogen levels Regulated?
The positive regulation of circulating fibrinogen levels is primarily controlled at the transcriptional level by inflammatory cytokines, notably IL-6, which activates the JAK/STAT3 pathway and induces C/EBPbeta, leading to increased expression of FGA, FGB, and FGG. Additional layers of regulation include post-transcriptional mechanisms and secretion efficiency. Metabolic and inflammatory signals, such as IL-33/soluble ST2 and angiopoietin-like protein 8, can modulate systemic inflammation and indirectly influence fibrinogen levels [3,8]. Phospholipase A2-IIA and matrix metalloproteinases may also contribute to the regulation of coagulation homeostasis [4,5]. Extracellular matrix interactions through integrins and growth factors affect hepatocyte and endothelial function, potentially impacting fibrinogen secretion.
positive regulation of circulating fibrinogen levels and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FGA | Liver fibrosis; dysfibrinogenemia | Hepatocyte-specific knockout or point-mutation knock-in in mice |
| IL6 | Inflammation; acute-phase response | IL6 knockout mice or hepatocyte-specific overexpression |
| IL1RL1 | Acute aortic dissection; inflammation | Soluble ST2 overexpression or knockout in vascular smooth muscle cells [2,3] |
| PLA2G2A | Malignancy; coagulation disorders | CRISPR knockout in cancer cell lines followed by cytokine profiling |
| ANGPTL8 | Thoracic aortic dissection; metabolic inflammation | Liver-specific overexpression or knockout in mouse models |
Acute Aortic Dissection
Elevated circulating fibrinogen levels are observed in patients with acute aortic dissection, and soluble ST2 has been identified as a novel biomarker for this condition. Matrix metalloproteinase 9 and toll-like receptor 4 are also elevated, suggesting a link between inflammation, extracellular matrix remodeling, and fibrinogen regulation. Angiopoietin-like protein 8 levels are increased in thoracic aortic dissection and correlate with inflammatory conditions, further implicating fibrinogen dysregulation.
Malignancies
Plasma levels of phospholipase A2-IIA, an inflammatory enzyme, are associated with prognosis in patients with different types of malignancies and correlate with coagulation biomarkers, including fibrinogen. This suggests that positive regulation of circulating fibrinogen levels may contribute to cancer-associated thrombosis and disease progression.
Liver Fibrosis
A 5.9 kDa C-terminal fragment of the fibrinogen alpha chain has been shown to precede fibrosis progression in patients with liver disease, indicating that proteolytic processing of fibrinogen is linked to fibrogenesis. This highlights the importance of understanding how fibrinogen levels and fragments are regulated in chronic liver disease.
Inflammation and Metabolic Disorders
The interleukin-33/soluble ST2 axis plays a dual and context-dependent role in obesity and adipose tissue inflammation, which can influence systemic coagulation and fibrinogen levels. Targeting this axis may modulate fibrinogen-associated inflammatory responses.
From positive regulation of circulating fibrinogen levels-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does hepatocyte-specific knockout of FGA reduce circulating fibrinogen? | Liver-specific FGA knockout mouse (Cre-loxP) |
| Does a point mutation in STAT3 affect fibrinogen transcription? | STAT3 point-mutation knock-in via CRISPR in hepatocytes |
| Can overexpression of IL-6 increase fibrinogen levels? | Adeno-associated virus-mediated IL-6 overexpression in mouse liver |
| Does tagging endogenous FGB with a fluorescent reporter alter secretion? | Knock-in of GFP tag at FGB locus using CRISPR |
| What is the role of soluble ST2 in aortic dissection-related fibrinogen changes? | IL1RL1 knockout or overexpression in vascular cells [2,3] |
| Does ANGPTL8 regulate fibrinogen levels in metabolic stress? | ANGPTL8 knockout and overexpression in hepatocytes |
How to Study the positive regulation of circulating fibrinogen levels Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | mRNA expression of fibrinogen genes and regulators | Identify transcriptional changes in hepatocytes |
| ELISA | Circulating fibrinogen protein concentration | Clinical biomarker measurement [2,4] |
| Mass spectrometry | Fibrinogen fragments and modifications | Detect proteolytic processing in liver disease |
| CRISPR knockout screening | Genes affecting fibrinogen secretion | Discover novel regulators in hepatoma cells |
| Western blot | Protein levels of fibrinogen chains | Validate knockout or overexpression models |
| Immunohistochemistry | Tissue distribution of fibrinogen | Assess liver synthesis and deposition |
| Flow cytometry | Intracellular fibrinogen in hepatocytes | Measure secretion efficiency |
| Proximity ligation assay | Protein-protein interactions | Study fibrinogen assembly and secretion |
Transcriptional profiling (RNA-seq)
RNA sequencing of hepatocytes or liver tissue can quantify mRNA levels of FGA, FGB, FGG, and upstream regulators such as IL6 and STAT3, providing insights into transcriptional control of fibrinogen production.
Proteomic and immunoassays
Plasma fibrinogen levels can be measured by ELISA or immunoturbidimetry, while mass spectrometry-based proteomics can identify fibrinogen fragments and post-translational modifications [4,6].
CRISPR screening
Genome-wide CRISPR knockout or activation screens in hepatocyte cell lines can identify genes that positively or negatively regulate fibrinogen secretion, followed by validation with targeted knockouts.
Imaging and extracellular matrix studies
Live-cell imaging of fluorescently tagged fibrinogen can track secretion dynamics, while extracellular matrix composition can be analyzed to understand how matrix interactions influence fibrinogen levels.
How CRISPR Can Be Used to Study GO:0061755 positive regulation of circulating fibrinogen levels
Knockout
CRISPR knockout of FGA, FGB, or FGG in hepatocyte cell lines or mouse liver can abolish fibrinogen production, providing a baseline to study positive regulation. Knockout of upstream regulators like IL6 or STAT3 can reveal their contribution to circulating fibrinogen levels.
Point Mutation
Introducing point mutations in fibrinogen genes or regulatory elements via CRISPR base editing or homology-directed repair can model dysfibrinogenemia and dissect specific residues required for secretion or function.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) at endogenous fibrinogen loci enables real-time tracking of protein synthesis and secretion. Knock-in of disease-associated mutations can create accurate models for studying fibrinogen regulation in disease.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of fibrinogen genes or upstream cytokines like IL-6 can elevate circulating fibrinogen levels, mimicking acute-phase responses and allowing study of downstream effects.
How EDITGENE Supports positive regulation of circulating fibrinogen levels Research
Researchers studying positive regulation of circulating fibrinogen levels-related genes often need to determine whether a candidate gene is causally involved in fibrinogen production, secretion, or clearance. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of circulating fibrinogen levels research.
Frequently Asked Questions About positive regulation of circulating fibrinogen levels
What is GO:0061755?
GO:0061755 is a Gene Ontology biological process term defined as any process that increases the quantity of fibrinogen circulating in the bloodstream.
What genes are involved in positive regulation of circulating fibrinogen levels?
Key genes include FGA, FGB, FGG, IL6, STAT3, CEBPB, and inflammatory mediators such as IL33 and ANGPTL8 [1,3,8].
How are circulating fibrinogen levels measured?
Plasma fibrinogen is typically measured by ELISA, immunoturbidimetry, or mass spectrometry-based proteomics [4,6].
What diseases are associated with high fibrinogen levels?
Elevated fibrinogen is linked to acute aortic dissection, malignancies, liver fibrosis, and inflammatory conditions [2,4,5,6,8].
Can CRISPR be used to study fibrinogen regulation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect genes regulating fibrinogen levels.
What is the role of IL-6 in fibrinogen production?
IL-6 activates STAT3 and C/EBPbeta, leading to increased transcription of fibrinogen genes in hepatocytes.
How does liver fibrosis relate to fibrinogen?
A 5.9 kDa fragment of the fibrinogen alpha chain precedes fibrosis progression, indicating proteolytic processing is involved.
What is the link between aortic dissection and fibrinogen?
Soluble ST2, MMP9, TLR4, and ANGPTL8 are elevated in acute aortic dissection and correlate with fibrinogen dysregulation [2,5,8].
What experimental models are used to study fibrinogen regulation?
Liver-specific knockout mice, CRISPR-edited hepatocyte cell lines, and overexpression systems are commonly used [1,6].
Why is positive regulation of fibrinogen important in cancer?
Phospholipase A2-IIA correlates with coagulation biomarkers in malignancies, suggesting fibrinogen upregulation contributes to cancer-associated thrombosis.
Conclusion
GO:0061755, positive regulation of circulating fibrinogen levels, is a critical biological process at the intersection of coagulation, inflammation, and metabolism. Dysregulation of this process contributes to thrombotic and inflammatory diseases, including acute aortic dissection, malignancies, and liver fibrosis [2,4,5,6,8]. Advances in CRISPR-based models and bioinformatics are enabling precise dissection of the genes and pathways that control fibrinogen levels. Continued research in this area promises to uncover new biomarkers and therapeutic targets for a range of human diseases.
References
- 1. Bateman RM et al.. 2016. 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016.. Crit Care 20(Suppl 2):94 PMID: 27885969
- 2. Wang Y et al.. 2018. Magnitude of Soluble ST2 as a Novel Biomarker for Acute Aortic Dissection.. Circulation 137(3):259-269 PMID: 29146682
- 3. Casado M et al.. 2026. Dual and context-dependent role of the interleukin-33/soluble suppression of tumorigenicity 2 axis in obesity and adipose tissue inflammation.. Mol Med 32(1) PMID: 41814156
- 4. Menschikowski M et al.. 2013. Plasma levels of phospholipase A2-IIA in patients with different types of malignancies: prognosis and association with inflammatory and coagulation biomarkers.. Pathol Oncol Res 19(4):839-46 PMID: 23722320
- 5. Li T et al.. 2018. Serum levels of matrix metalloproteinase 9 and toll-like receptor 4 in acute aortic dissection: a case-control study.. BMC Cardiovasc Disord 18(1):219 PMID: 30497388
- 6. Marfà S et al.. 2014. Lack of a 5.9 kDa peptide C-terminal fragment of fibrinogen α chain precedes fibrosis progression in patients with liver disease.. PLoS One 9(10):e109254 PMID: 25275549
- 7. Maniotis AJ et al.. 2002. Control of melanoma morphogenesis, endothelial survival, and perfusion by extracellular matrix.. Lab Invest 82(8):1031-43 PMID: 12177242
- 8. Yang Y et al.. 2020. Increased Circulating Angiopoietin-Like Protein 8 Levels Are Associated with Thoracic Aortic Dissection and Higher Inflammatory Conditions.. Cardiovasc Drugs Ther 34(1):65-77 PMID: 32034642
